Table 3.

Frequency of participants meeting the primary outcome measure of seroresponse^* against ≥5 vaccine serotypes at 4 weeks after vaccination.

Group	N	Frequency per group (95% CI)	Groups compared	% Difference (95% CI)	P value#
Vaccine PCV-10	114	65% (55%,74%)	PCV-23 vs. PCV-10	1% (−12%, 13%)	1.00
Vaccine PPV-23	110	65% (56%,74%)	PCV-10 vs. Placebo	65% (55%,74%)	<0.0001
Placebo	113	0% (0%,3%)	PCV-23 vs. Placebo	65% (56%,74%)	<0.0001

^*Seroresponse was defined by ≥2-fold increase in antibody concentrations at 4 weeks post-vaccination compared with pre-vaccination.

^#Fisher’s Exact Test.